Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 724

Results For "IP"

11103 News Found

Asahi Kasei completes construction of microcrystalline cellulose plant
News | February 18, 2023

Asahi Kasei completes construction of microcrystalline cellulose plant

With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC


Patient care is an imperative dimension in providing quality healthcare: Dr. Bharati Pravin Pawar
News | February 18, 2023

Patient care is an imperative dimension in providing quality healthcare: Dr. Bharati Pravin Pawar

The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals


Dr. Mandaviya hails eSanjeevani milestone of providing telemedicine services to 10 Cr patients
News | February 18, 2023

Dr. Mandaviya hails eSanjeevani milestone of providing telemedicine services to 10 Cr patients

eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation


Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg
Drug Approval | February 18, 2023

Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg

Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)


Lupin receives EIR from USFDA for injectable facility in Nagpur
News | February 18, 2023

Lupin receives EIR from USFDA for injectable facility in Nagpur

The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022


Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
Drug Approval | February 18, 2023

Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing

Themis will market this drug with the brand name REMITHEM.


GUERISON enters Indian Ophthalmology market
News | February 17, 2023

GUERISON enters Indian Ophthalmology market

The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes


AstraZeneca Pharma India receives no objection for Durvalumab
Drug Approval | February 17, 2023

AstraZeneca Pharma India receives no objection for Durvalumab

Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer


Biocon Q3 FY23 revenue up 36%
News | February 17, 2023

Biocon Q3 FY23 revenue up 36%

The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses


Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData
News | February 17, 2023

Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData

According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year